AssetMark Inc’s Sinovac Biotech, Ltd SVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $0 | Buy |
63
+37
| +142% | – | ﹤0.01% | 3689 |
|
|
2026
Q1 | $0 | Hold |
26
| – | – | ﹤0.01% | 3623 |
|
|
2025
Q4 | $0 | Buy |
26
+2
| +8% | – | ﹤0.01% | 3492 |
|
|
2025
Q3 | $0 | Hold |
24
| – | – | ﹤0.01% | 3279 |
|
|
2025
Q2 | $0 | Buy |
+24
| New | – | ﹤0.01% | 3151 |
|
|
2024
Q4 | – | Sell |
-21
| Closed | – | – | 2686 |
|
|
2024
Q3 | $0 | Buy |
21
+5
| +31% | – | ﹤0.01% | 2394 |
|
|
2024
Q2 | $0 | Buy |
16
+3
| +23% | – | ﹤0.01% | 2273 |
|
|
2024
Q1 | $0 | Hold |
13
| – | – | ﹤0.01% | 2169 |
|
|
2023
Q4 | $0 | Sell |
13
-1
| -7% | – | ﹤0.01% | 2033 |
|
|
2023
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 1831 |
|
|
2023
Q2 | $0 | Buy |
+14
| New | – | ﹤0.01% | 1717 |
|
|
2023
Q1 | – | Sell |
-14
| Closed | – | – | 1735 |
|
|
2022
Q4 | $0 | Hold |
14
| – | – | ﹤0.01% | 1690 |
|
|
2022
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 1662 |
|
|
2022
Q2 | $0 | Buy |
14
+4
| +40% | – | ﹤0.01% | 1737 |
|
|
2022
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 1808 |
|
|
2021
Q4 | $0 | Hold |
10
| – | – | ﹤0.01% | 1681 |
|
|
2021
Q3 | $0 | Buy |
+10
| New | – | ﹤0.01% | 1564 |
|
|
2017
Q1 | – | Sell |
-39
| Closed | – | – | 1563 |
|
|
2016
Q4 | $0 | Buy |
+39
| New | +$235 | ﹤0.01% | 1481 |
|
Other funds holding SVA
AssetMark Inc's SVA Position: Q2 2026 in Review
AssetMark Inc increased its Sinovac Biotech, Ltd (SVA) stake by 142% in Q2 2026, adding 37 shares and bringing the position to 63 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3689.
AssetMark Inc first reported a position in SVA in Q4 2016 and has held it in 18 quarters since. 8 funds tracked by Wall St. Rank hold SVA as of Q2 2026.
- AssetMark Inc held 63 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
- AssetMark Inc bought 37 Sinovac Biotech, Ltd shares in Q2 2026.
- Sinovac Biotech, Ltd made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3689 holding.
- AssetMark Inc first reported a position in Sinovac Biotech, Ltd in Q4 2016 and has held it in 18 quarters since.
- 8 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.